November 18, 2015
Asahi Kasei Pharma Corp.

Asahi Kasei Pharma's licensing partner, Dong-A ST Co., Ltd. (Dong-A ST), obtained approval on November 13, 2015, from Korea's Ministry of Food and Drug Safety (MFDS) for the sale of Teribone™ osteoporosis drug (generic name: teriparatide acetate; product name in Japan: Teribone™ 56.5 µg subcutaneous injection) for the treatment of osteoporosis in postmenopausal women at high risk of bone fracture.

Asahi Kasei Pharma and Dong-A ST concluded a license agreement in October 2014 granting Dong-A ST exclusive rights for the development and sale of Teribone™ in Korea, and Dong-A ST filed an application for approval in December 2014. Dong-A ST will begin the sale of Teribone™ in Korea in the spring of 2016.

Asahi Kasei Pharma believes that through Dong-A ST's effort to quickly facilitate its widespread use, Teribone™ will make a significant contribution to the treatment of osteoporosis in Korea.

Corporate profile of Dong-A ST Co., Ltd.

President: Kang Soo-Hyoung
Head office: Seoul, Korea
Paid-in capital: 38.5 billion won
Business line: Manufacture and sale of pharmaceuticals
Net sales: 568.1 billion won (January-December 2014)
Employees: 1,582 (as of December 31, 2014)

Press Releases

distributed by